Skip to main content
OpenTrials
Completed

NCT Number: NCT02767960

Serum Tenascin-C Concentration in Patients With Acute Coronary Syndrome

This study valuates the serum Tenascin-C concentration in patients with acute coronary syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Coronary Syndrome Cardiovascular Diseases Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, 116011, China

About this study

It is found that Tenascin-C plays an important role in ventricular remodeling, heart failure, aortic dissection, rheumatic heart disease and other cardiovascular diseases, which may be a new marker for the diagnosis and prognosis prediction of these diseases. However, there is few relevant studies about the Tenascin-C concentration in patients with acute coronary syndrome.This study valuates the serum Tenascin-C concentration in patients with acute coronary syndrome.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

.diagnosed as acute coronary syndrome,including STEMI,non-STEMI,and UAP.

  • with left ventricular ejection fraction（LVEF）>=45%
  • written informed consents are obtained
  • admitted within 24 hours after chest pain attacked

Exclusion criteria

  • complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy
  • complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction
  • with acute or chronic infection, surgery or trauma in the last month
  • secondary hypertension, severe liver dysfunction,severe renal insufficiency
  • with abnormal thyroid function or allergy to iodine agent
  • refusal to sign the informed consent

Treatment and study plan

Primary outcomes

  1. Serum Tenascin-C concentration

    Time frame: 12 months

    Serum Tenascin-C concentration in ng/ml

Secondary outcomes

  1. Relationship between Tenascin-C and high sensitive C reaction protein (hs-CRP) concentration

    Time frame: 12 months

    With or without association between them

  2. Relationship between Tenascin-C and Troponin-I (Tn-I) concentration

    Time frame: 12 months

    With or without association between them

  3. MACEs during 12-month follow-up

    Time frame: 12 months

    All major adverse cardiac events( MACEs) including death, myocardial infarction, angina, heart failure are recorded.

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital of Dalian Medical University

Other

Registry information

Official study title

Change of Serum Tenascin-C Concentration and the Relationship With Hs-CRP，cTnI and Prognosis in Patients With Acute Coronary Syndrome

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
May 11, 2016
Registry last updated
Aug 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.